DrugBiological
Elotuzumab clinical trials
Also written Empliciti, HuLuc63 and BMS-901608.
- studies test it
- 45
- open now
- 2
- in phase 3
- 7
- first study started
- 2006
Keep track of what changes. Save the elotuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
45 studies that test it; most in 2017 (6)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 31
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 27
Bristol-Myers Squibb (12) · M.D. Anderson Cancer Center (3) · University of Arkansas (3) · Mayo Clinic (2) · AbbVie (1) · Yale University (1) · Abdullah Khan (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Dexamethasone (20) · Lenalidomide (12) · Pomalidomide (7) · Bortezomib (5) · Carfilzomib (4) · Iberdomide (3) · Daratumumab (2) · Etentamig (1)
Studies
Open first, then newest update. How each study uses elotuzumab is read from its arms, and is right about nine times in ten.
Testing it · 45
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingPhase 1/2Omar Nadeem, MDNCT06518551Written as Elotuzumab
- Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingPhase 1/2Mayo ClinicNCT06785415Written as Elotuzumab
- Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02420860Written as Elotuzumab
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 3AbbVieNCT06158841Written as Elotuzumab
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 3CelgeneNCT03651128Written as Elotuzumab
- Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04517851Written as Elotuzumab
- Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaActive, not recruitingPhase 1/2Yale UniversityNCT05002816Written as Elotuzumab
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingPhase 1Abdullah KhanNCT05981209Written as Elotuzumab
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple MyelomaCompletedPhase 1/2SWOG Cancer Research NetworkNCT01668719Written as Elotuzumab
- Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedPhase 2Bristol-Myers SquibbNCT02719613Written as Elotuzumab
- LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaCompletedPhase 2Wake Forest University Health SciencesNCT03361306Written as Elotuzumab
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)TerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04918147Written as elotuzumab
- A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingPhase 2Massachusetts General HospitalNCT02718833Written as Elotuzumab
- Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedPhase 2University of ChicagoNCT02969837Written as Elotuzumab
- Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaActive, not recruitingPhase 2Washington University School of MedicineNCT03030261Written as Elotuzumab
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaActive, not recruitingEarly Phase 1Icahn School of Medicine at Mount SinaiNCT05560399Written as Elotuzumab
- Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedPhase 2Mayo ClinicNCT03713294Written as Elotuzumab
- Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedPhase 2M.D. Anderson Cancer CenterNCT01729091Written as Elotuzumab
- Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedPhase 2Dana-Farber Cancer InstituteNCT02375555Written as Elotuzumab
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnPhase 2University of ArkansasNCT03000634Written as Elotuzumab
See all 45 studies that test elotuzumab →
Given in every arm · 11 — elotuzumab is usual care beside what is tested
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Elotuzumab
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingPhase 2Medical College of WisconsinNCT04835129Written as Elotuzumab
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingPhase 1/2CelgeneNCT03989414Written as Elotuzumab
- FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedPhase 1Fate TherapeuticsNCT04614636Written as Elotuzumab
- E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedPhase 2Dana-Farber Cancer InstituteNCT02279394Written as Elotuzumab
- An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedPhase 3Bristol-Myers SquibbNCT02726581Written as Elotuzumab
- Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary AmyloidosisStatus unknownPhase 2Barbara Ann Karmanos Cancer InstituteNCT03252600Written as Elotuzumab
- A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedPhase 2Bristol-Myers SquibbNCT02612779Written as Elotuzumab
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnPhase 2Dana-Farber Cancer InstituteNCT03227432Written as Elotuzumab
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedPhase 1PETHEMA FoundationNCT03023527Written as Elotuzumab
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT02252263Written as Elotuzumab
As the comparator · 7 — what is tested is compared with elotuzumab
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as Elotuzumab
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 3Regeneron PharmaceuticalsNCT05730036Written as Elotuzumab
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as Elotuzumab
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06208150Written as Elotuzumab
- A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple MyelomaActive, not recruitingPhase 3European Myeloma Network B.V.NCT05028348Written as Elotuzumab
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedPhase 1/2Multiple Myeloma Research ConsortiumNCT04150965Written as Elotuzumab, pomalidomide, dexamethasone
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnPhase 3CelgeneNCT06232707Written as Elotuzumab
Codes
What other systems call elotuzumab · ClinicalTrials.gg INT005550
- MeSH (NLM) C546027elotuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1351PE5UGSELOTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1726104Confirmed FDA, Wikidata
- Wikidata Q3723645elotuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66982ElotuzumabOne source FDA
- DrugBank DB06317One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546027 | elotuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1351PE5UGS | ELOTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1726104 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3723645 | elotuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66982 | Elotuzumab | One source FDA |
| DrugBank | DB06317 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.